Circulating TGF-β Pathway in Osteogenesis Imperfecta Pediatric Patients Subjected to MSCs-Based Cell Therapy

Area of Science:

• Biochemistry
• Genetics
• Cell Biology

Background:

• Osteogenesis Imperfecta (OI) is a rare genetic disorder causing bone fragility, often due to COL1A1/COL1A2 gene mutations.
• Current treatments for OI, primarily antiresorptive drugs, have limitations in effectiveness and safety.
• Mesenchymal stem cell (MSC) therapy and TGF-β pathway inhibition are emerging therapeutic strategies for OI.

Purpose of the Study:

• To investigate the serum TGF-β signaling pathway in pediatric Osteogenesis Imperfecta patients.
• To explore the impact of Mesenchymal Stem Cell (MSC) therapy on TGF-β signaling in OI patients.

Main Methods:

• Analysis of serum expression and bioactivity of TGF-β superfamily members in two pediatric OI patients undergoing MSC therapy (TERCELOI trial).
• Assessment of TGF-β pathway modulation following reiterative MSC infusions.

Main Results:

• The most severe OI patient exhibited enhanced basal serum expression and bioactivity of TGF-β superfamily members.
• MSC therapy modulated the observed TGF-β pathway alterations in the treated OI patients.

Conclusions:

• The study highlights a potential role for TGF-β signaling in Osteogenesis Imperfecta pathogenesis.
• MSC therapy may influence the TGF-β pathway, suggesting a novel therapeutic mechanism for OI.